Prostate Cancer
Clinical Trials

1) First Line Metastatic mCRPC: USO #19191: BMS CA209-7DX: A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (Check-Mate 7DX: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX)

2) Cohort 21 and 23 part of XL184-021 EXELIXIS: A Phase Ib Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors (More information under Prostate Cancer/Solid Tumors Section)

Send UsA Message

    Call Now Button